Pharmacological removal of human Ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574)

Molecular Pharmacology

Volumn 77, Issue 1, 2010, Pages 58-68

  Gerlach, Aaron C ^a   Stoehr, Sally J ^a   Castle, Neil A ^a  

^a Icagen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 3 NITRO N (4 PHENOXYPHENYL)BENZAMIDE; BEKM 1; BENZAMIDE DERIVATIVE; ICA 105574; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL STIMULATING AGENT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ELECTRIC POTENTIAL; EMBRYO; GENE ACTIVATION; GENE INACTIVATION; GUINEA PIG; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART VENTRICLE; HUMAN; HUMAN CELL; HYPERPOLARIZATION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; WHOLE CELL;

ACTION POTENTIALS; ANIMALS; CELLS, CULTURED; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HUMANS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PYRIDINES;

EID: 73549100431     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.059543     Document Type: Article

References (36)

1. Casis O, Olesen SP, and Sanguinetti MC (2006) Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol 69:658-665.
2. + current to repolarization of the human ventricular action potential. Prog Biophys Mol Biol 96:357-376.
3. Food and Drug Administration and HHS (2005a) International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist 70:61134-61135.
4. Food and Drug Administration and HHS (2005b) International Conference on Harmonisation; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability. Notice. Fed Regist 70:61133-61134.
5. Gordon E, Lozinskaya IM, Lin Z, Semus SF, Blaney FE, Willette RN, and Xu X (2008) 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]- nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Mol Pharmacol 73:639-651.
6. Grunnet M, Hansen RS, and Olesen SP (2008) hERG1 channel activators: a new anti-arrhythmic principle. Prog Biophys Mol Biol 98:347-362.
7. Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, and Grunnet M (2006a) Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol Pharmacol 69:266-277.
8. Hansen RS, Diness TG, Christ T, Wettwer E, Ravens U, Olesen SP, and Grunnet M (2006b) Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1 H-tetrazol-5-yl)-phenyl)-N′-(3′-trifluoromethylphenyl) urea]. Mol Pharmacol 70:1319-1329.
9. Hansen RS, Olesen SP, Rønn LC, and Grunnet M (2008) In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig. J Cardiovasc Pharmacol 52:35-41.
10. Hill AP, Campbell TJ, Bansal PS, Kuchel PW, and Vandenberg JI. (2007a) The S631A mutation causes a mechanistic switch in the block of hERG channels by CnErg1. Biophys J 93:L32-L34.
11. + channel by the scorpion toxin CnErg1. Biophys J 92:3915-3929.
12. 2+ destabilization of the inactivated state. Biophys J 77:2534-2541.
13. + channel. Mol Pharmacol 67:827-836.
14. Kiehn J, Lacerda AE, and Brown AM (1999) Pathways of HERG inactivation. Am J Physiol 277:H199-H210.
15. Milnes JT, Dempsey CE, Ridley JM, Crociani O, Arcangeli A, Hancox JC, and Witchel HJ (2003) Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett 547:20-26.
16. Mitcheson JS (2008) hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol 21:1005-1010.
17. Mitra R and Morad M (1985) A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates. Am J Physiol 249:H1056-H1060.
18. Morita H, Wu J, and Zipes DP (2008) The QT syndromes: long and short. Lancet 372:750-763.
19. + channels: function and dysfunction. Prog Biophys Mol Biol 98:137-148.
20. Perry M, Sachse FB, and Sanguinetti MC. (2007) Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc Natl Acad Sci U S A 104:13827-13832.
21. Sanguinetti MC and Mitcheson JS (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26:119-124.
22. Sanguinetti MC and Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.
23. Schönherr R and Heinemann SH (1996) Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J Physiol 493:635-642.
24. Smith PL, Baukrowitz T, and Yellen G (1996) The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379:833-836.
25. Spector PS, Curran ME, Zou A, Keating MT, and Sanguinetti MC (1996) Fast inactivation causes rectification of the IKr channel. J Gen Physiol 107:611-619.
26. Su Z, Limberis J, Souers A, Kym P, Mikhail A, Houseman K, Diaz G, Liu X, Martin RL, Cox BF, et al. (2009) Electrophysiologic characterization of a novel hERG channel activator. Biochem Pharmacol 77:1383-1390.
27. Thomas D, Karle CA, and Kiehn J (2006) The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des 12:2271-2283.
28. Trudeau MC, Warmke JW, Ganetzky B, and Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269:92-95.
29. Tseng GN, Sonawane KD, Korolkova YV, Zhang M, Liu J, Grishin EV, and Guy HR (2007) Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling. Biophys J 92:3524-3540.
30. Weerapura M, Hébert TE, and Nattel S (2002) Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers Arch 443:520-531.
31. Xu X, Recanatini M, Roberti M, and Tseng GN (2008) Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243). Mol Pharmacol 73:1709-1721.
32. Yang BF, Xu DH, Xu CQ, Li Z, Du ZM, Wang HZ, and Dong DL (2004) Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels. Acta Pharmacol Sin 25:554-560.
33. Zeng H, Lozinskaya IM, Lin Z, Willette RN, Brooks DP, and Xu X (2006) Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J Pharmacol Exp Ther 319:957-962.
34. Zhang M, Korolkova YV, Liu J, Jiang M, Grishin EV, and Tseng GN (2003) BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys J 84:3022-3036.
35. Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA, Sun Z, and Cordes JS (2005) Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 68:876-884.
36. + channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. J Physiol 509:129-137.